
News|Articles|January 3, 2025
Top 5 Conference Coverage Items of 2024
Author(s)MHE Staff
The year's top conference coverage item shares the effects of "Ozempic Bod" and "Ozempic Face," as presented at the annual American Academy of Ophthalmology meeting in Chicago.
Advertisement
- The Ozempic Bod Gets Trimmer, ‘Ozempic Face’ Gets Older | AAO 2024
 Rapid weight loss from the glucagon-like peptide 1 (GLP-1s) can reduce fat tissue in face that makes for a smooth, more youthful appearance, says AAO presenter.Read here 
- Chronic Viral Infections Common in Those with HIV | AIDS 2024
 An overview of the complex relationships between herpes simplex virus, human papillomavirus, cytomegalovirus and HIV.Read here 
- GLP-1 Tiering Agreement Reached, Says Optum Rx President
 Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing.Read here 
- William Shatner Discusses Stage 4 Melanoma Diagnosis, Treatment | AAD 2024
 The 92-year-old "Star Trek" star said the skin cancer was treated surgically and with immunotherapy. It was apparently the first time he had discussed his melanoma in public.Read here 
- Immigrants and Undocumented People Face Significant Health Challenges in the United States | 2024 ATS
 Discrimination, fear and lack of knowledge are just a few of the obstacles they face when trying to access healthcare.Read here 
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Understanding Hemophilia A and B
2
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations
3
Nonfactor agents for hemophilia prophylaxis: A Q&A with Steven Pipe, M.D.
4
Payers Are Bracing for the Specialty Trend of the Future | AMCP Nexus 2025
5



















































